Pediatric Neurooncology
- Functional and Structural Genomics
- KiTZ

Prof. Dr. Stefan Pfister
Head of Division
Pediatric Neurooncology is currently a vibrant field of research. This is desperately needed, since brain tumors have become the number one cause of cancer-related mortality in children. Our group aims to bridge the gap between generating genomic screening data as well as faithful models for preclinical drug testing, and exploiting these data for the sake of our patients.

Our Research
The first goal includes the identification, validation and clinical application of prognostic and predictive biomarkers in different childhood brain tumors, including genome, transcriptome and epigenome analysis, and integrative bioinformatics approaches. The second major focus involves the generation of suitable in vitro and in vivo models for systematic pre-clinical testing of novel smart drugs, often in combination with established cytotoxic drugs, chemotherapy or immunotherapy. These novel therapies are ultimately translated into patient care, tightly linked with thorough patient selection based on the genetic/molecular signature of the individual tumor (“personalized cancer care”).
Future Outlook
The thorough understanding of the immense biological heterogeneity of childhood brain tumors is a prerequisite for targeted treatment approaches. Thus, we will continue to comprehensively investigate the entire genetic and epigenetic diversity of childhood brain tumors within and across histopathological entities. Many of these novel methods are currently being prepared for routine diagnostic applications in a clinical setting through our nationally and internationally acting molecular diagnostics programs (www.pediatric-neurooncology.com). Preclinical models will allow us to specifically test biological hypotheses gained from genome-wide primary tumor analyses in vitro and in vivo, before they are recommended for use in patients. Another focus will be the analysis of clonality within tumors, their respective metastases, and tumor relapses, by ultra-deep next-generation and single-cell sequencing techniques. As a third major focus, we have started focusing on the detection of tumor-specific alteration in body fluids, such as cerebrospinal fluid and plasma, which can be exploited for molecular diagnostics, tumor cell clearance (minimal residual disease), detection of molecular targets, and primary resistance mechanisms. Finally, we will evaluate novel as well as many conventional therapies systematically for their inter-individual range in pharmacokinetics. These differences might help explaining successes and failures in individual patients.
Team
90 Employees
-
Prof. Dr. Stefan Pfister
Head of Division
-
Olfat Ahmad
MNP Outreach Scientific Coordinator
-
Michelle Arnet
-
Dr. Robert Autry
Group Leader
-
Lindsy Autry
Fundraising
-
Leonhard Valentin Bamberg
-
Daniela Bastian
Fundraising
-
Luisa Becker
-
Corinna Becki
-
Dr. Patricia Benites Goncalves da Silva
-
Enrique Blanco Carmona
-
Christian Jörg Braun
-
Carmen Büsken
-
Alessia Cais
-
Dr. Aylin Camgöz
-
Karla Catacora Castaneda
-
Chun Ho Chan
-
Dr. Lioba Courth
Scientific Project Management
-
Hannah Dörsam
-
Olga Ermakova
-
Paula Ertel
-
Selina Faoual
-
Tom Fischer
-
Dr. Asta Försti
-
Larissa Fritzenschaf
-
Katia Fundter
Fundraising
-
Neal Geisemeyer
-
Tobias Gies
-
Johannes Gojo
-
Dr. Apurva Gopisetty
-
Dr. Diego Yair Grinman
Postdoc
-
Nele Haberstumpf
-
Michael Hain
IT
-
Sema Hamurcu
-
Islam Hassanin
-
Sophie Henneken
-
Martin Herdt
-
Nicola Herrmann-Wichmann
-
Nina Hofmann
-
Ines Hofmann
Sekretariat
-
Dr. Natalie Jäger
-
Dr. Pascal Johann
-
Dr. Piyush Kumar Joshi
-
Rolf Kabbe
-
Carolin Kerber
-
Dr. Benedikt Kirchner
-
Eric Konrath
-
Dr. Marcel Kool
Group Leader
-
Dr. Kendra Maaß
Group Leader
-
Norman Mack
-
Lukas Madenach
-
Monika Mauermann
-
Luise Meder
-
Dennis Metselaar
-
Sophia Montigel
-
Dr. Alexandra Moosmann
-
Jasmin Luisa Müller
Secretariat
-
Jan Müller
-
David Norali Ghasemi
-
Martha O'Brien
-
Dr. Iris Oezen
Scientific Project Management
-
Dr. Konstantin Okonechnikov
-
Dr. Kristian Pajtler
Group Leader
-
Lena Parzer
-
Areeba Jamilkhan Patel
-
Maria Proksch
-
Franziska Reinelt
-
Johanna Rettenmeier
-
Dr. Eva-Maria Rief
-
Dr. Iman Sadeghi Dehchesmeh
-
Franziska Schelb
-
Frederike Scheurer
-
Mathis Schilling
-
Svenja Schmitt
-
Benjamin Schwalm
-
Nathalie Schwarz
-
Dr. Martin Sill
-
Nike Simon
-
Julia Sundheimer
-
Niclas Thiebach
-
Dr. Supat Thongjuea
Group Leader
-
Elias Ulrich
-
Torben Wagner
-
Esther Wahlbrink
-
Shanzheng Wang
-
Tatjana Wedig
-
Samuel Zabel
-
Eric Zhao
-
Dr. Wencan Zhu
-
Dr. Marc Zuckermann
Group Leader
Selected Publications
Active medulloblastoma enhancers reveal subgroup-specific cellular origins.
Lin, C.Y., Erkek, S. et al., …and Pfister, S.M.*, Bradner, J.E.*, Northcott, P.A.*
Molecular Classification of Ependymal Tumors across All CNS Compartments, Histopathological Grades, and Age Groups.
Pajtler KW, Witt H, Sill M et al., …and Kool, M.*, Pfister, S.M.*
Enhancer hijacking activates GFI1 family oncogenes in medulloblastoma.
Northcott, P. et al., …and Peter Lichter, P.*, Korbel, J.O.*, Wechsler-Reya, R*, Pfister, S.M.*
Genome Sequencing of SHH Medulloblastoma Predicts Genotype-Related Response to Smoothened Inhibition.
Kool M et al.,…,and Wechsler-Reya, R.J.*, Lichter, P.*, Pfister, S.M*.
Get in touch with us

